Swiss drugmaker Roche has abandoned global diverse workforce targets and compatriot Novartis is ending its use of diverse ...

Among measures taken, Roche said its Chief Diversity Offices in the U.S. and at its Basel headquarters "will focus on ...

Oxford BioTherapeutics has partnered with Roche to discover novel potentially first-in-class antibody-based therapeutics for the treatment of cancer.

Investigators said that the OLE study showed Roche’s gantenerumab dropped the risk of developing Alzheimer's symptoms by 50%.

Roche Holding (ROCH:CA) now has a Canadian dollar hedged Canadian Depositary Receipt, but it currently lacks liquidity. Read ...

Roche, which put billions on the line a year ago across several ADC pacts, kicked off 2025 by returning to Innovent Biologics ...

Angesichts des Drucks der Trump-Regierung hat der Schweizer Pharmariese Roche seine seit langem bestehenden globalen ...

Roche’s up to $1 billion investment will provide access to Oxford BioTherapeutics’ antibody-drug conjugate platform for ...

Meanwhile, fellow Swiss company Novartis will no longer use diverse panels in its hiring process for U.S.-based employees, ...

This A-List features two lists of sequencing instrument providers: eight for NGS instruments and three for Sanger ...

The inquiry is the latest effort by the European Commission and European countries to scrutinize potential antitrust behavior ...

Swiss pharmaceutical giant Roche is cutting its global diversity workforce targets, aligning with recent U.S. legal changes ...